--- schema_version: "secwatch.filing_event.v1" accession: "0001140361-24-032101" form_type: "8-K" ticker: null cik: "0001850266" company_name: "Akili, Inc." filed_at: "2024-07-02T23:59:59+00:00" generated_at: "2026-05-31T23:49:55.110242+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # Akili completes acquisition by Virtual Therapeutics at $0.4340 per share; stock to be delisted ## Summary - Tender offer closed with 69,674,538 shares (88.2%) validly tendered at $0.4340 per share; merger completed July 2, 2024. - All outstanding shares converted to right to receive Offer Price; company becomes wholly owned subsidiary of Virtual Therapeutics. - Board of directors resigned; Daniel J. Elenbaas becomes sole director; Matt McIntire named Treasurer and Secretary. - Nasdaq listing suspended; Form 25 to be filed to delist shares; registration to be terminated on Form 15. ## SEC filing metadata - accession: 0001140361-24-032101 - form_type: 8-K - cik: 0001850266 - company_name: Akili, Inc. - filed_at: 2024-07-02T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/ny20031954x1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001140361-24-032101 - JSON: https://secwatch.observer/filing/0001140361-24-032101.json - Plain text: https://secwatch.observer/filing/0001140361-24-032101.txt ## Key facts - Executive change Daniel J. Elenbaas was appointed as Director at Akili, Inc.. - Action: appointed - Role: Director source text: The sole director of Purchaser immediately prior to the Effective Time was Daniel J. Elenbaas. evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - Executive change Daniel J. Elenbaas was appointed as President at Akili, Inc.. - Action: appointed - Role: President source text: Daniel J. Elenbaas, serving as President evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - Executive change Christine Lemke resigned as Director at Akili, Inc.. - Action: resigned - Role: Director source text: each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - Executive change Mary Hentges resigned as Director at Akili, Inc.. - Action: resigned - Role: Director source text: each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - Executive change Matt McIntire was appointed as Treasurer and Secretary at Akili, Inc.. - Action: appointed - Role: Treasurer and Secretary source text: Matt McIntire, serving as Treasurer and Secretary evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - Executive change William "BJ" Jones, Jr. resigned as Director at Akili, Inc.. - Action: resigned - Role: Director source text: each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - Executive change W. Edward Martucci II resigned as Director at Akili, Inc.. - Action: resigned - Role: Director source text: each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - Executive change Matthew Franklin resigned as Director at Akili, Inc.. - Action: resigned - Role: Director source text: each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - Executive change John Spinale resigned as Director at Akili, Inc.. - Action: resigned - Role: Director source text: each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - Executive change Adam Gazzaley resigned as Director at Akili, Inc.. - Action: resigned - Role: Director source text: each of Matthew Franklin, Adam Gazzaley, M.D., Ph.D., Mary Hentges, William “BJ” Jones, Jr., Christine Lemke, W. Edward Martucci II, Ph.D., and John Spinale resigned from the board of directors of the Company. evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm - M&A Transactions Akili, Inc. underwent a change of control involving Virtual Therapeutics Corporation (Parent) and Alpha Merger Sub, Inc. (Purchaser) for $0.4340 per share (closed 2024-07-02). - Action: change of control - Counterparty: Virtual Therapeutics Corporation (Parent) and Alpha Merger Sub, Inc. (Purchaser) - Consideration: $0.4340 per share - Closing: 2024-07-02 source text: offer to purchase all of the C ompany’s outstanding shares of common stock, par value $0.0001 per share (the “ Common Stock ”), for a price per share of the Common Stock of $0.4340 (the “ Offer Price ”), payable subject to any applicable tax withholding and without interest, all subject to and in accordance with the terms and conditions set forth in the evidence_url: https://www.sec.gov/Archives/edgar/data/1850266/000114036124032101/0001140361-24-032101-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.